Mpox Clade Ib Case Detected in New York Resident After Travel

The New York State Department of Health has reported the first confirmed case of mpox clade Ib in a state resident following international travel. This development marks the initial detection of this specific mpox clade in New York, including New York City.

According to health officials, the affected individual is currently receiving medical care and is being kept in isolation until symptoms resolve. Authorities have stated that there is no known local transmission of mpox clade Ib in the community or elsewhere in the state at this time.

Mpox clade I, which includes clade Ib, has been associated with more severe illness compared to clade II, based on information from public health agencies. The New York State Department of Health has said that the risk of local transmission to the broader community remains low.

Previous travel-associated cases of mpox clade Ib have been documented in other U.S. states, including New Hampshire and California. In all reported U.S. cases, international travel has been identified as a common factor.

What the numbers show

• 1 mpox clade Ib case confirmed in New York State
• Clade I mpox cases in the U.S. have all involved international travel
• Earlier clade Ib cases reported in New Hampshire and California

Health authorities have indicated that the individual diagnosed with mpox clade Ib remains in isolation to prevent any possible spread until symptoms have fully resolved. The department has emphasized that, as of the latest update, there are no signs of local transmission in New York communities.

Surveillance efforts by the CDC and local partners continue across the United States. These activities include clinical monitoring, laboratory testing, epidemiological investigations, and wastewater analysis to identify and respond to mpox cases.

Mpox clade I has been noted by health departments to cause more severe disease than clade II. The recent New York case follows a pattern seen in other states, where travel outside the country has preceded diagnosis.

The New York State Department of Health and other agencies remain engaged in ongoing monitoring and public communication regarding mpox cases. Officials continue to update guidance as new information becomes available from surveillance and case investigations.

* This article is based on publicly available information at the time of writing.